FDC Q1 Revenue at Rs 6.48 Billion, Margins Dip Slightly

08 Aug 2025 CW Team

FDC Limited has reported a steady performance for the quarter ended 30 June 2025 (Q1 FY26), with operating revenue of Rs 6.48 billion, reflecting a year-on-year (YoY) growth of 1.6 per cent.

The India formulation business recorded revenue of Rs 5.79 billion, showing a 5.6 per cent YoY rise and contributing 90 per cent to total consolidated sales. The API segment also delivered modest growth of 3.3 per cent YoY, with sales of Rs 260 million. However, export formulations dropped 33.8 per cent YoY to Rs 420 million, while emerging market revenue declined 39 per cent YoY to Rs 260 million due to supply disruptions.

The US business showed early signs of recovery, with Rs 116 million in sales during Q1 FY26, representing a 106 per cent YoY growth in direct supplies. This growth follows the resolution of recall-related issues and updated API impurity standards clarified by the US FDA. Despite this progress, overall US business revenue fell 22.2 per cent YoY due to lower profit share from partners caused by reduced sales in FY25.

FDC’s EBITDA for the quarter stood at Rs 1.4 billion, with a margin of 21.6 per cent, down from 23 per cent in the previous year. The drop is mainly due to increased strategic expenses, notably a 271.4 per cent YoY surge in R&D expenditure to Rs 85 million and higher employee costs linked to field force expansion and ORS manufacturing capacity enhancements.

Business Performance Summary – Q1 FY26 (Rs crore):

Net Sales: Rs 648 crore | 1.6% YoY growth
India Formulations: Rs 579 crore | 5.6% YoY growth
US Formulations: Rs 16 crore | -22.2% YoY decline
Emerging Markets: Rs 26 crore | -39.3% YoY decline
API Sales: Rs 26 crore | 3.3% YoY growth

According to IQVIA secondary sales data (MAT June 30, 2025), FDC outpaced the Indian Pharmaceutical Market (IPM) with 10.8 per cent growth versus 8.0 per cent for IPM. Its flagship brand, Electral, climbed to 14th place in IPM rankings, up from 18th the previous year. Electral also became the fastest-growing product among IPM’s top 20 and the first FDC brand to cross Rs 6 billion in IPM sales.

Export formulation sales were Rs 420 million, accounting for 6 per cent of total sales, while the API business represented 4 per cent with Rs 260 million in revenue.

Despite short-term supply challenges in emerging markets, FDC maintains a healthy order pipeline and expects improved execution in subsequent quarters.

FDC Limited has reported a steady performance for the quarter ended 30 June 2025 (Q1 FY26), with operating revenue of Rs 6.48 billion, reflecting a year-on-year (YoY) growth of 1.6 per cent.The India formulation business recorded revenue of Rs 5.79 billion, showing a 5.6 per cent YoY rise and contributing 90 per cent to total consolidated sales. The API segment also delivered modest growth of 3.3 per cent YoY, with sales of Rs 260 million. However, export formulations dropped 33.8 per cent YoY to Rs 420 million, while emerging market revenue declined 39 per cent YoY to Rs 260 million due to supply disruptions.The US business showed early signs of recovery, with Rs 116 million in sales during Q1 FY26, representing a 106 per cent YoY growth in direct supplies. This growth follows the resolution of recall-related issues and updated API impurity standards clarified by the US FDA. Despite this progress, overall US business revenue fell 22.2 per cent YoY due to lower profit share from partners caused by reduced sales in FY25.FDC’s EBITDA for the quarter stood at Rs 1.4 billion, with a margin of 21.6 per cent, down from 23 per cent in the previous year. The drop is mainly due to increased strategic expenses, notably a 271.4 per cent YoY surge in R&D expenditure to Rs 85 million and higher employee costs linked to field force expansion and ORS manufacturing capacity enhancements.Business Performance Summary – Q1 FY26 (Rs crore):Net Sales: Rs 648 crore | 1.6% YoY growthIndia Formulations: Rs 579 crore | 5.6% YoY growthUS Formulations: Rs 16 crore | -22.2% YoY declineEmerging Markets: Rs 26 crore | -39.3% YoY declineAPI Sales: Rs 26 crore | 3.3% YoY growthAccording to IQVIA secondary sales data (MAT June 30, 2025), FDC outpaced the Indian Pharmaceutical Market (IPM) with 10.8 per cent growth versus 8.0 per cent for IPM. Its flagship brand, Electral, climbed to 14th place in IPM rankings, up from 18th the previous year. Electral also became the fastest-growing product among IPM’s top 20 and the first FDC brand to cross Rs 6 billion in IPM sales.Export formulation sales were Rs 420 million, accounting for 6 per cent of total sales, while the API business represented 4 per cent with Rs 260 million in revenue.Despite short-term supply challenges in emerging markets, FDC maintains a healthy order pipeline and expects improved execution in subsequent quarters.

Infrastructure Urban

06 Apr 2026

CFI Appoints New National Council for FY27 and FY28

The Construction Federation of India (CFI) has announced its newly elected National Council and office bearers for a two-year term covering FY27 and FY28. M. V. Satish, Advisor to CMD and Lead Ambassador for Middle East, L&T, has been elected President; Priti Patel, Chief Strategy & Growth Officer, Tata Projects, has been appointed Vice President; and Ajit Bhate, Managing Director, Precast India Infrastructures, has taken charge as Treasurer.The newly formed National Council brings together senior leaders from major EPC and infrastructure companies, reflecting CFI’s continued focus o..

Real Estate

06 Apr 2026

India REIT Market Gains Momentum with Strong Returns

India’s Real Estate Investment Trust (REIT) market is witnessing strong growth, emerging as a competitive investment avenue both domestically and across Asia. According to a recent ANAROCK report released at EXCELERATE 2026 by NAREDCO Maharashtra NextGen, the sector is evolving into a mature asset class driven by solid fundamentals, regulatory backing and rising investor confidence.The introduction of Small and Medium REITs (SM REITs) in 2025 has further widened access through fractional ownership, unlocking a potential monetisation opportunity of Rs 670–710 billion. Indian REITs have deli..

Real Estate

06 Apr 2026

Domicil Debuts In Tricity With Luxe 9 Showcase

Domicil Germany, a luxury home furnishing brand from the House of HTL International, has made its Tricity debut with an exclusive showcase at Luxe 9, marking its first retail presence in the region.The invite-only event brought together architects, interior designers, real estate developers and high-net-worth individuals, reflecting rising demand for globally inspired, design-led living spaces.Centred on the theme ‘Celebrate Living with Timeless German Design’, the showcase highlighted Domicil’s focus on combining craftsmanship, functionality and refined aesthetics. Attendees experienced..